Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753312 | 0.86 | ADORA2A (0.43) | ADORA2AADORA1PFKFB3ADORA3ADORA2B | |
| SCHEMBL8218304 | 0.83 | LMNA (0.43) | ADORA2AADORA1ADORA3MEN1KMT2A | |
| SCHEMBL23943222 | 0.81 | CD274 (0.46) | ADORA2AADORA1POLQDHODHFYN | |
| SCHEMBL3752597 | 0.78 | ADORA2A (0.41) | ADORA2AADORA1ADORA3ADORA2BDHODH | |
| SCHEMBL3752403 | 0.78 | ADORA2A (0.41) | ADORA2AADORA1PFKFB3ADORA3DHODH | |
| SCHEMBL3757598 | 0.77 | ADORA2A (0.39) | ADORA2AADORA1PFKFB3ADORA3ADORA2B | |
| SCHEMBL8213830 | 0.75 | ADORA2A (0.39) | ADORA2AADORA1DHODHKMT2A | |
| SCHEMBL3755649 | 0.74 | DHODH (0.47) | ADORA2AADORA1DHODH | |
| SCHEMBL3763504 | 0.72 | AAK1 (0.39) | ADORA2AADORA1DHODHFYN | |
| SCHEMBL18835664 | 0.70 | KDM4E (0.38) | ADORA2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | ADORA2A 509/4885ADORA1 454/4885PFKFB3 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.